Marisa Wexler, MS,  senior science writer—

People with Sjögren’s disease who received the experimental therapy ianalumab (VAY736) in Phase 3 clinical trials reported greater reductions in disease activity than those given a placebo within two months of starting treatment. That’s according to new data ianalumab’s developer, Novartis, shared at the American College of Rheumatology…

An experimental therapy from Ouro Medicines is being tested in a Phase 1b clinical trial on people who have Sjögren’s disease or idiopathic inflammatory myopathy (IMM), another autoimmune condition. “This study reflects Ouro’s strategy of expanding OM336 development to additional immune-mediated diseases where an ‘immune reset’ approach would…

A machine learning tool that can analyze certain molecules in stool samples may help to better diagnose primary Sjögren’s disease, according to a new study from researchers in China. The team found that their novel model, using fecal samples, could distinguish primary Sjögren’s patients from healthy individuals with an…

Primary Sjögren’s disease-associated interstitial lung disease (pSjD-ILD) — a form of Sjögren’s disease that’s characterized by scarring in the lungs — tends to lead to worse outcomes in biological males than in females, a new study reports. “Our retrospective study revealed that in patients with pSjD-ILD, male individuals were…

A traditional Chinese medicine formulation called Qihuang Jianpi ZiShen Granule (QJZG) may help to alleviate Sjögren’s disease by reducing inflammatory molecules and associated tissue damage, according to computer simulations and tests in a cell model of the disease. “This study provides evidence supporting the use of Chinese medicine…

Using artificial intelligence (AI) to analyze biopsies of the salivary glands in people with Sjögren’s disease may help identify patients who are likely to have disease involvement in vital organs, a new study reports. According to the researchers, the novel model developed by the team “achieves high accuracy in…

Efgartigimod is entering a Phase 3 clinical trial after data from a proof-of-concept Phase 2 trial showed it outperformed a placebo at easing symptoms and signs of primary Sjögren’s disease, the treatment’s developer said. Argenx shared the data at the European Congress of Rheumatology (EULAR) 2025, held June…

A study found significant associations between eye surface changes and alterations in immune activity throughout the body in people with primary Sjögren’s disease. “These results provide new insights into the relationship between ocular surface and systemic [whole body] status in patients with [primary Sjögren’s disease],” the researchers wrote. The study,…

Cullinan Therapeutics is planning the launch of a clinical trial in the U.S. to test its treatment candidate CLN-978 in people with Sjögren’s disease. The study will be open to Sjögren’s patients whose disease is active and moderate to severe, and who are positive for anti-SSA/Ro antibodies and/or…

Immunovant is planning to launch a potentially registrational clinical trial this summer to test its treatment candidate IMVT-1402 in people with Sjögren’s disease. The company said that its investigational new drug application — a formal request to the U.S. Food and Drug Administration (FDA) seeking permission to start…